Patient Adherence to Glucagon Like Peptide-1 Receptor Agonists in Obesity Management: A Narrative Review of Real-World Evidence
Maaen Journal for Medical Sciences · 31.01.2026 · 5 (1)
DOI: 10.55810/2789-9136.1091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Maaen Journal for Medical Sciences, online erschienen am 31.01.2026. Verfasst von Zainab M. Al-Shammaa und 4 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Obesity has become a widespread public health problem in many regions of the world. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a dual effect on glycemic control and weight loss. Liraglutide, semaglutide, and dulaglutide were first used in the management of type 2 diabetes (T2D), and their use is now growing among people without diabetes. Obesity management requires long-term or even lifelong interventions, so adherence to prescribed therapy is critical for achieving weight loss and maintaining it over time. Patient adherence to GLP-1RAs varies depending on the medication used, its dosing frequency, and whether findings come from clinical trials or real-world settings. According to the previous studies, semaglutide (Ozempic® and Wegovy®) tends to show better adherence than others. In contrast, liraglutide (Saxenda®) consistently shows lower adherence, often below 20% after one year in real-world data. Dulaglutide (Trulicity®) falls somewhere in the middle, with reported adherence of about 44% over 12 months. This review has highlighted several key insights that are essential for clinicians aiming to support long-term use of GLP-1RAs in obesity care. In conclusion, while GLP-1RAs offer significant benefits in obesity management, achieving sustained weight loss requires more than just initiating therapy; it demands an ongoing, patient-centered approach that supports patients throughout their journey.
Zitieren
APA
Al-Shammaa, Z. M., Attash, H. M., Almallah, R. S., Thamer, A., & Saleem, F. (2026). Patient Adherence to Glucagon Like Peptide-1 Receptor Agonists in Obesity Management: A Narrative Review of Real-World Evidence. Maaen Journal for Medical Sciences, 5(1). https://doi.org/10.55810/2789-9136.1091
Vancouver
Al-Shammaa ZM, Attash HM, Almallah RS, Thamer A, Saleem F. Patient Adherence to Glucagon Like Peptide-1 Receptor Agonists in Obesity Management: A Narrative Review of Real-World Evidence. Maaen Journal for Medical Sciences. 2026;5(1). doi:10.55810/2789-9136.1091
BibTeX
@article{AlShammaa2026,
author = {Al-Shammaa, Zainab M. and Attash, Heba M. and Almallah, Rahma S. and Thamer, Abdulla and Saleem, Fahad},
title = {Patient Adherence to Glucagon Like Peptide-1 Receptor Agonists in Obesity Management: A Narrative Review of Real-World Evidence},
journal = {Maaen Journal for Medical Sciences},
year = {2026},
volume = {5},
number = {1},
doi = {10.55810/2789-9136.1091}
}
EUVIMED